# Early Cognitive Decline in Down Syndrome – Neuroimaging Supplement

> **NIH NIH R01** · UNIVERSITY OF ALABAMA IN TUSCALOOSA · 2022 · $404,276

## Abstract

ABSTRACT
Down syndrome (DS) is the most common genetic cause of intellectual disability and occurs in about 1 in 700
infants. Adults with DS are at high risk for premature cognitive decline and increased incidence of Alzheimer’s
disease (AD). Virtually all individuals with DS over 30 years of age have the hallmark AD neuropathology of
beta amyloid plaques and neurofibrillary tangles. Certain cognitive functions decline in DS between 30 and 40
years old and the decline is predictive of later AD diagnosis, yet few longitudinal studies have examined
younger individuals. Individuals with DS in late adolescence and early adulthood likely have begun to exhibit
neuropathology of AD, but AD diagnosis itself is extremely rare. The broad, long-term objective of the parent
project, Early Cognitive Decline in Down Syndrome (R01HD098179), is to identify cognitive skills that show
early decline in individuals with DS during late adolescence into early adulthood. This longitudinal study,
conducted at the University of Alabama (UA) and the University of California Davis (UCD), will enroll
participants with DS aged 15-25 years and follow them for three years. The goal of the proposed
supplement is to add neuroimaging to the existing parent R01, and thereby help to contribute to the
identification of a set of unique indicators of early cognitive decline and that foreshadow subsequent
AD in individuals with DS. Neuroimaging markers will also be evaluated in conjunction with blood biomarkers
for AD collected through the first administrative supplement. Aim 1 of the present supplement is to acquire
structural, diffusion, perfusion, and resting state fMRI scans in 30 participants with DS at each site (60 total)
using innovative strategies designed to help individuals with intellectual disability participate in MRI research.
Imaging will coincide with the first time point of behavioral data collection from the parent grant. Aim 2 is to
quantify multi-modal anatomical and vascular neuroimaging biomarkers of AD, including cortical morphometry,
hippocampal subfields, white matter microstructure and cerebrovascular disease, cerebral blood flow, and
network connectivity using image processing pipelines developed by the UC Davis Alzheimer’s Disease
Research Center Neuroimaging Core. Neuroimaging biomarkers will be assessed in relation to concurrent
cognitive and behavioral measures as well as in relation to blood biomarkers such as plasma concentrations of
Aβ, tau protein, and neurofilament light chains (NfL). At the conclusion of the parent R01, neuroimaging
biomarkers will be evaluated as predictors of cognitive decline assessed through the parent R01 over a three-
year period after the MRI scan. Quantified neuroimaging data and raw images will be made available for
sharing with other researchers through the INCLUDE Data Coordinating Center (DCC). Adding AD-sensitive
MRI indices has the potential to greatly enhance the value of the neurocognitive, behavioral, and blood-bas...

## Key facts

- **NIH application ID:** 10670637
- **Project number:** 3R01HD098179-03S1
- **Recipient organization:** UNIVERSITY OF ALABAMA IN TUSCALOOSA
- **Principal Investigator:** FRANCES A CONNERS
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $404,276
- **Award type:** 3
- **Project period:** 2020-07-15 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10670637

## Citation

> US National Institutes of Health, RePORTER application 10670637, Early Cognitive Decline in Down Syndrome – Neuroimaging Supplement (3R01HD098179-03S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10670637. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*